Cell & Gene Collaborative Blog

  1. The “Swifty's” Guide To The Top 5 Cell & Gene Manufacturing Evolutions In 2021 1/10/2022

    The Top 5 article is simultaneously one of the greatest joys and most excruciatingly difficult tasks I willingly inflict upon myself every year. What I never anticipated, however, is just how well my annual takeaways on the CGT manufacturing paradigm evolutions could also be complemented by the titles and lyrics of Taylor Swift’s biggest hits.

  2. Cell & Gene Therapy Manufacturing Leadership: An Evolving Definition 1/7/2022

    This article is the last in a five-part series unpacking the Top 5 Cell & Gene Therapy Manufacturing Evolutions in 2021. We started our countdown at #5 with the CGT talent crunch and progressed down through next-gen delivery (#4), cell culture challenges (#3), and knowledge management (#2). We’ve finally made it to what I think is the most exciting, evolving trend of them all.

  3. CGT Manufacturing Resolution #1: Brace For Continued — But Nuanced — Investments In Manufacturing & Infrastructure 1/6/2022

    In the first of this five-part article, Spink dives into resolution #1, encouraging companies to celebrate the surge of investments in the CGT manufacturing space — albeit with a few small caveats

  4. In A Build Or Buy World, Knowledge Management Is The Real Consideration 1/6/2022

    This article is the fourth in a five-part series unpacking the Top 5 Cell & Gene Therapy Manufacturing Evolutions in 2021— counting down from #5 to #1. In the three previous installments, we covered the talent crunch (#5), the push towards next-generation delivery efforts (#4), and our ongoing war with cell culture (#3). Here, we progress ever closer to #1 — but starting first with #2.

  5. In A CGT Galaxy Close, Close To Us All, The “Cell Wars” Are (Not Really) Brewing 1/5/2022

    This article is the third in a five-part series unpacking the Top 5 Cell & Gene Therapy Manufacturing Evolutions in 2021— counting down from #5 to #1. In the two previous installments, we covered the talent crunch (#5) and the push towards next-generation delivery efforts (#4). Here, we continue our journey towards #1 with #3.

  6. CGT Manufacturing In 2022 (And Beyond): Expectations, Predictions, & Wildest Dreams 1/4/2022

    In the fall, I had several great conversations with executives in the cell and gene therapy (CGT) space about what the year ahead has in store for the CGT manufacturing sector. Together, their perspectives present a well-rounded overview of the areas demanding the most brainpower, financial resources, and innovation in the CGT manufacturing sector today.

  7. Talent Crunch Compels Cell & Gene Industry, Applicants To Get Creative 1/3/2022

    This article is the first in a five-part series unpacking the Top 5 Cell & Gene Therapy Manufacturing Evolutions in 2021. We’ll be counting down from #5 to #1, starting here with #5.

  8. “Ancillary Materials” 12/16/2021

    On the 2nd-12th days of Christmas, ARW gave to me…

  9. ARW's C&G Manufacturing Must-Reads (Holiday Edition!) 12/16/2021

    Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format and send them out via email. Here’s a “permanent” copy of my C&G Manufacturing Must-Reads newsletter that was delivered on December 16th, for all you practical people who, like comedian George Carlin, abhor the question, “Where is it?”

  10. Scott Gottlieb: Plotting The Trajectory Of Cell & Gene Therapy CMC 12/10/2021

    I recently had the immense fortune to briefly meet former FDA commissioner Dr. Scott Gottlieb and pick his brain on how he expects the advanced therapies development paradigm has evolved and will continue to advance in the years ahead.